Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	146	110	67	203	68	14
Market Cap Growth	145.72%	64.77%	-66.97%	197.98%	374.28%	148.91%
Enterprise Value	62	22	-44	66	28	2
PE Ratio	-	-3.66	-2.48	-9.83	-3.04	-0.83
PB Ratio	1.70	1.21	0.57	1.47	2.50	1.09
P/FCF Ratio	-12.10	-5.26	-3.22	-12.29	-5.87	-1.57
P/OCF Ratio	-12.12	-5.27	-3.22	-12.30	-5.88	-1.57
EV/EBITDA Ratio	-4.77	-0.72	1.64	-3.21	-1.59	-0.10
EV/EBIT Ratio	-4.76	-0.72	1.63	-3.21	-1.59	-0.10
EV/FCF Ratio	-7.59	-1.04	2.12	-4.01	-2.45	-0.19
Debt / Equity Ratio	-	-	-	-	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	0.00	0.00
Debt / FCF Ratio	-	-	-	-	0.00	-0.01
Quick Ratio	15.78	16.92	19.94	43.66	2.53	9.59
Current Ratio	16.34	17.61	21.23	45.18	2.73	10.83
Return on Equity (ROE)	-31.30%	-29.50%	-21.30%	-14.60%	-158.60%	-105.70%
Return on Assets (ROA)	-29.90%	-28.50%	-20.70%	-14.40%	-117.10%	-97.50%
Return on Capital (ROIC)	-36.45%	-34.47%	-23.47%	-14.86%	-53.73%	-130.73%
Earnings Yield	-20.35%	-27.29%	-40.29%	-10.17%	-32.84%	-120.26%
FCF Yield	-12.78%	-19.00%	-31.06%	-8.13%	-17.03%	-63.73%
Buyback Yield / Dilution	1.03%	0.43%	-8.27%	-934.13%	-33.09%	-104.36%
Total Shareholder Return	1.03%	0.43%	-8.27%	-934.13%	-33.09%	-104.36%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).